Biotech Financing Entering New Phase

A Rothstein Kass report finds that biotechnology executives are becoming more creative in their financing approaches, creating a climate ripe for consolidation and strategic alliances. Investors who viewed an initial public offering as an exit strategy are being replaced by those with longer horizons and by better capitalized industry participants eager to explore synergies.